Search Antibody Database

Found 1 matching record:

Displaying record number 1332

Download this epitope record as JSON.

MAb ID	168B8
HXB2 Location	gp160(296-317) DNA(7110..7175)	gp160 Epitope Map
Author Location	gp120( BaL)
Research Contact	Abraham Pinter, Lab. of Retrovirology, Public Research Institute, pinter@phri.org
Epitope	`CTRPNYNKRKHIGPGRAF`	Epitope Alignment
Subtype	B
Ab Type	gp120 V3 // V3 glycan (V3g)
Neutralizing
Species (Isotype)	humanized mouse(IgG2κ)
Patient
Immunogen	vaccine
Keywords	antibody binding site, vaccine antigen design

Vaccine Details

Vaccine type	gp120-CD4 complex
Vaccine component	gp120
Adjuvant	Ribi adjuvant (MPL+TDM) (RIBI)

Notes

Showing 1 of 1 note.

168B8: Vaccination of a gp120-CD4 fusion complex in six transgenic XMG2 XenoMouse mice that produce human IgG2 with K light chain did not produce any neutralizing antibodies. 36/39 MAbs derived from one of these mice were in one of two competition groups that were conformational and specific for the complex, suggesting this chimeric vaccine may be of little value, as immunodominant responses are to epitopes unique to the complex, not present in native Env. This MAb is one of the 3/36 non-neutralizing MAbs that bound to linear epitopes on gp120. He2003 (antibody binding site, vaccine antigen design)

References

Showing 1 of 1 reference.

He2003 Yuxian He, Paul D'Agostino, and Abraham Pinter. Analysis of the Immunogenic Properties of a Single-Chain Polypeptide Analogue of the HIV-1 gp120-CD4 Complex in Transgenic Mice That Produce Human Immunoglobulins. Vaccine, 21(27-30):4421-4429, 1 Oct 2003. PubMed ID: 14505925. Show all entries for this paper.